Analysis of blood metabolites after HBAIC1808 intake.

Analysis of blood metabolites after HBAIC1808 intake. - Analysis of blood HBAIC1808 metabolites.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000034281

Enrollment

Registered

2018-09-27

Start date

2018-09-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy adults

Interventions

-Oral administration of a placebo capsule and collecting blood samples. -Oral administration of an active drink every day for 3 weeks. --Oral administration of an active capsule and collecting blood

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Healthy male

Exclusion criteria

Exclusion criteria: -Subjects who go to hospital regularly or routinely taking oral medicine for disease: gastrointestinal system, liver, kidney, heart, and blood pressure. -Subjects who had been took an antibiotic for over a week within 4 weeks. -Subjects who are deemed inappropriate to participate in this study by the principle investigator.

Design outcomes

Primary

Measure	Time frame
Identification of HBAIC1808 metabolites after oral intake	—

Secondary

Measure	Time frame
Change of blood inflammatory markers after 3 weeks of HBAIC1808 administration.	—

Countries

Japan

Contacts

Public ContactTetsuya Kuwano

Kao Corporation R&D -Core Technology- Biological Science Research

kuwano.tetsuya@kao.com+81-285-68-7459

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026